Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Post by Chianchinon Apr 30, 2023 6:51am
166 Views
Post# 35421384

What Mugsy will not tell you...

What Mugsy will not tell you...Endo made billions " not milion? in sales and the share price were in above$30 US and lots of profits. Endo was not in LATAM but mostly north America and Europe. Then prices for generic drug market changed for the worst more or less at the same time when GUD went all in in LATAM and bought GBT for nearly half a billion $$. more or less. GUD never made a cent profit on the purchase of GBT years later. If Endo could not survive with billions in sales how is GUD going to survive with sales made in devaluating pesos and inflation in place are up to 100%. Would any astute investor take advice from someone such with a Trak record like mugsy who whose record has been wrong and lost fortunes for ten consecutive years? You got to be nuts. He articulates cleverly may mean well but wrong and lost a fortune. 
<< Previous
Bullboard Posts
Next >>